Tamihiro Kawakami Selected Research

Vascular Skin Diseases

10/2021	Immune checkpoint molecule expression is altered in the skin and peripheral blood in vasculitis.
9/2021	The relationship between anti-phosphatidylserine/prothrombin complex IgM antibodies and cutaneous ulcers in patients with cutaneous vasculitis.
5/2021	Anti-phosphatidylserine/prothrombin complex antibodies in patients with cutaneous vasculitis: Possible involvement in the pathogenesis.
3/2020	Relationship between lysosomal-associated membrane protein-2 and anti-phosphatidylserine/prothrombin complex antibody in the pathogenesis of cutaneous vasculitis.
9/2011	Successful use of mizoribine in a patient with sarcoidosis and cutaneous vasculitis.
11/2010	Microscopic polyangiitis associated with antiphospholipid antibodies and immune complex mediated cutaneous vasculitis.
5/2009	Differences in anti-phosphatidylserine-prothrombin complex antibodies and cutaneous vasculitis between regular livedo reticularis and livedo racemosa.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tamihiro Kawakami Research Topics

Disease

15	Vasculitis (Vasculitides) 05/2022 - 06/2007
10	Polyarteritis Nodosa (Periarteritis Nodosa) 07/2017 - 12/2007
8	Microscopic Polyangiitis 01/2016 - 01/2006
7	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 01/2022 - 01/2006
7	Vascular Skin Diseases 10/2021 - 05/2009
7	Atopic Dermatitis (Atopic Eczema) 09/2014 - 10/2003
6	Pemphigus (Pemphigus Vulgaris) 01/2018 - 07/2012
6	Purpura 08/2011 - 06/2007
5	Churg-Strauss Syndrome (Allergic Angiitis) 04/2021 - 06/2007
5	Pruritus (Itching) 06/2012 - 10/2003
3	Melanoma (Melanoma, Malignant) 04/2022 - 01/2016
3	IgA Vasculitis (Purpura, Schoenlein Henoch) 01/2022 - 02/2010
3	Systemic Vasculitis 10/2021 - 01/2013
3	Arteritis 05/2021 - 12/2013
3	Bullous Pemphigoid (Pemphigoid) 01/2021 - 03/2009
3	Erythema elevatum diutinum 09/2011 - 02/2010
3	Livedo Reticularis 03/2011 - 06/2007
3	Behcet Syndrome (Behcet's Syndrome) 02/2009 - 11/2003
2	Thrombophlebitis 07/2022 - 02/2009
2	Disseminated Intravascular Coagulation 07/2022 - 04/2019
2	Vitiligo 04/2022 - 09/2002
2	Ulcer 09/2021 - 09/2015
2	Mononeuropathies (Mononeuritis Multiplex) 04/2021 - 12/2013
2	Neoplasms (Cancer) 10/2017 - 05/2009
2	Thrombosis (Thrombus) 01/2017 - 06/2007
2	Granulomatosis with Polyangiitis (Wegener's Granulomatosis) 01/2016 - 02/2010
2	Asthma (Bronchial Asthma) 07/2013 - 07/2005
2	Eosinophilia 07/2013 - 01/2009
2	Nephritis 12/2010 - 02/2010
2	Cutaneous Leukocytoclastic Vasculitis (Hypersensitivity Angiitis) 02/2010 - 04/2008
2	Hypersensitivity (Allergy) 05/2009 - 01/2009
2	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 12/2007 - 12/2005
1	Macrophage Activation Syndrome 07/2022
1	Erythema Nodosum 07/2022
1	Blister (Bulla) 04/2022
1	Hematuria 01/2022
1	Heart Failure 04/2021
1	Kyrle disease 12/2020
1	Thrombotic Microangiopathies 04/2019

Drug/Important Bio-Agent (IBA)

15	AntibodiesIBA 09/2021 - 12/2007
13	Prothrombin (Factor II)IBA 09/2021 - 12/2007
11	PhosphatidylserinesIBA 09/2021 - 12/2007
10	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 05/2022 - 01/2006
10	Immunoglobulin M (IgM)IBA 09/2021 - 12/2007
8	AutoantibodiesIBA 01/2018 - 12/2005
7	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2021 - 02/2010
7	mizoribineIBA 07/2012 - 03/2009
7	Antiphospholipid AntibodiesIBA 08/2011 - 06/2007
5	Peroxidase (Myeloperoxidase)IBA 07/2022 - 01/2006
5	Antigen-Antibody Complex (Immune Complex)IBA 05/2022 - 06/2007
5	Immunoglobulin A (IgA)IBA 01/2022 - 04/2008
5	Immunoglobulin G (IgG)IBA 05/2021 - 12/2007
5	Therapeutic UsesIBA 09/2015 - 08/2008
5	Lupus Coagulation Inhibitor (Lupus Anticoagulant)IBA 08/2011 - 12/2007
4	Proteins (Proteins, Gene)FDA Link 07/2022 - 12/2005
3	Histones (Histone)IBA 07/2022 - 03/2020
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/2021 - 02/2014
3	Intravenous Immunoglobulins (IVIG)FDA Link 04/2021 - 01/2009
3	Prednisolone (Predate)FDA LinkGeneric 12/2013 - 03/2011
3	Histamine Antagonists (Antihistamines)IBA 07/2012 - 10/2003
3	Warfarin (Coumadin)FDA LinkGeneric 03/2011 - 02/2010
2	Cadherins (E-Cadherin)IBA 04/2022 - 07/2013
2	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 05/2009
2	C-Reactive ProteinIBA 10/2021 - 12/2013
2	Immunoglobulins (Immunoglobulin)IBA 05/2021 - 11/2013
2	AutoantigensIBA 01/2021 - 02/2016
2	moesinIBA 07/2017 - 01/2017
2	Messenger RNA (mRNA)IBA 07/2017 - 11/2014
2	Biomarkers (Surrogate Marker)IBA 01/2016 - 09/2014
2	ImmunosorbentsIBA 01/2016 - 11/2013
2	EnzymesIBA 01/2016 - 11/2013
2	AntigensIBA 09/2013 - 01/2013
2	Interleukin-6 (Interleukin 6)IBA 05/2012 - 09/2009
2	EmollientsIBA 05/2012 - 06/2011
2	Clopidogrel (Plavix)FDA Link 02/2010 - 01/2010
2	Non-Sedating Histamine H1 Antagonists (Histamine H1 Antagonists, Non Sedating)IBA 08/2006 - 10/2003
2	Tryptases (Tryptase)IBA 08/2006 - 10/2003
2	Histamine (Histamine Dihydrochloride)FDA Link 08/2006 - 10/2003
1	Dacarbazine (DIC)FDA LinkGeneric 07/2022
1	IgA receptor (protein B)IBA 04/2022
1	Oxidoreductases (Dehydrogenase)IBA 04/2022
1	Discoidin Domain Receptor 1IBA 04/2022
1	Glycoproteins (Glycoprotein)IBA 04/2022
1	Protein Kinase InhibitorsIBA 04/2022
1	Immune Checkpoint ProteinsIBA 10/2021
1	B7-H1 AntigenIBA 10/2021
1	Programmed Cell Death 1 ReceptorIBA 10/2021
1	mepolizumabIBA 04/2021
1	Immunologic Factors (Immunomodulators)IBA 04/2021
1	KalininIBA 01/2021
1	Laminin (Merosin)IBA 01/2021
1	Matrix Metalloproteinases (MMPs)IBA 01/2021
1	Keratins (Keratin)IBA 12/2020
1	dabrafenibIBA 04/2019
1	trametinibIBA 04/2019
1	Deoxyribonuclease I (Nickase)IBA 01/2019

Therapy/Procedure

22	Therapeutics 04/2022 - 10/2003
1	Cell- and Tissue-Based Therapy (Cell Therapy) 04/2022
1	Tissue Transplantation 04/2022
1	Operative Surgical Procedures 04/2022